# Query Results

**Query:** corporate restructuring

**Timestamp:** 20251020_025629

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.3928 | **Semantic:** 0.5612 | **Keyword:** 0.0000 | **Rerank:** -3.8341

**Source:** ion-beam-applications-sa-financial-ratios-10-years-financial-data-marketscreener.md

**Chunk ID:** 171

**Content:**

```
et Writedown & Restructuring Costs | | | | | | - | - | - | - | - 
(Income) Loss On Equity Investments - (CF) | | | | | | 3.23M | 1.25M | -3K | 169K | 2.06M 
Stock-Based Compensation (CF) | | | | | | 130K | 800K | 9M | 1M | - 
Provision and Write-off of Bad Debts | | | | | | 2.9M | -287K | -749K | 457K | 2.55M 
Net Cash From Discontinued Operations | | | | | | - | - | - | - | - 
Other Operating Activities, Total | | | | | | 1.85M | -8.27M | -25.83M | -5.94M | -11.43M 
Change In Accounts Receivabl
```

---

## Result 2

**Similarity Score:** 0.3439 | **Semantic:** 0.4913 | **Keyword:** 0.0000 | **Rerank:** -6.1749

**Source:** ion-beam-applications-sa-financial-ratios-10-years-financial-data-marketscreener.md

**Chunk ID:** 170

**Content:**

```
7M | 9.64M 
Amortization of Goodwill and Intangible Assets - (CF) | | | | | | 1.46M | - | 327K | 250K | 269K 
Depreciation & Amortization, Total | | | | | | 10.24M | 8.37M | 9.32M | 10.02M | 9.91M 
Amortization of Deferred Charges, Total - (CF) | | | | | | 1.72M | 1.52M | 1.4M | 1.5M | 1.79M 
(Gain) Loss From Sale Of Asset | | | | | | - | - | - | - | - 
(Gain) Loss on Sale of Investments - (CF) | | | | | | -547K | 704K | -3.59M | 654K | 759K 
Asset Writedown & Restructuring Costs | | | | | | - |
```

---

## Result 3

**Similarity Score:** 0.3413 | **Semantic:** 0.4876 | **Keyword:** 0.0000 | **Rerank:** -7.2508

**Source:** iba-reports-solid-full-year-2024-results-iba-group.md

**Chunk ID:** 19

**Content:**

```
* **New segment reporting** following updated organization structure in **three focused entities:** IBA Clinical, IBA Technologies and IBA Corporate. New reporting will be applied as of 2025 with 2024 pro-forma available in Section III

* **CFO transition:** Henri de Romree, Deputy CEO, appointed interim CFO following the departure of Soumya Chandramouli
```

---

## Result 4

**Similarity Score:** 0.3411 | **Semantic:** 0.4873 | **Keyword:** 0.0000 | **Rerank:** -7.3425

**Source:** ion-beam-applications-iba-protect-enhance-and-save-lives-imd-business-school-for-management-and-lead.md

**Chunk ID:** 35

**Content:**

```
results and ultimately affected the share price. Finally, succession challenges were looming in top management, with the chief research officer (CRO) approaching retirement age and CEO Pierre Mottet having spent the last 24 years in the company. Learning Objective
Managing high tech developments, life science applications, positioning a technology, segmenting, growth management, IPO, buyout, carve-out, nuclear physics, proton therapies, cancer treatment.
```

---

## Result 5

**Similarity Score:** 0.3829 | **Semantic:** 0.5343 | **Keyword:** 0.0294 | **Rerank:** -7.6828

**Source:** ion-beam-applications-rsff.md

**Chunk ID:** 4

**Content:**

```
/governance-and-structure/shareholders/index)
 * [ Statutory bodies ](https://www.eib.org/en/about/governance-and-structure/statutory-bodies/index)
 * [ Control and evaluation ](https://www.eib.org/en/about/governance-and-structure/control-evaluation/index)
 * [ Organisation structure ](https://www.eib.org/en/about/governance-and-structure/organisation/index)
 * Corporate responsibility 
back
 * [ Overview ](https://www.eib.org/en/about/cr/index)
 * [ Providing finance ](https://www.eib.org/en/a
```

---

